Davis Polk advised AstraZeneca PLC in connection with its SEC-registered shelf takedown of $850 million aggregate principal amount of 3.500% notes due 2023, $400 million aggregate principal amount of floating rate notes due 2023, $1 billion aggregate principal amount of 4.000% notes due 2029 and $750 million aggregate principal amount of 4.375% notes due 2048.

AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialization of prescription medicines for three main therapy areas of healthcare: oncology; cardiovascular, renal and metabolism; and respiratory.

The Davis Polk corporate team included partner Leo Borchardt and associates Kate Darracott and Grace M. Cao. Counsel Alon Gurfinkel and associate Veronica Orecharova provided tax advice. Associate Jennifer Lin Ricci provided 1940 Act advice. Members of the Davis Polk team are based in the London and New York offices.

Copy link to share post